Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETHZ NASDAQ:KOD NASDAQ:SPRY NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETHZETHZilla$15.64-4.4%$0.00$6.60▼$174.60$257.12M0.38562,881 shs1.86 million shsKODKodiak Sciences$18.05-5.0%$11.86$1.92▼$19.39$953.44M2.67551,130 shs1.23 million shsSPRYARS Pharmaceuticals$9.72-1.8%$11.24$9.34▼$18.90$960.63M0.841.83 million shs1.17 million shsTNGXTango Therapeutics$8.66-3.7%$7.48$1.03▼$9.70$963.51M1.671.84 million shs1.57 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETHZETHZilla-4.44%-14.79%-35.34%+1,635,999,900.00%+1,635,999,900.00%KODKodiak Sciences+7.34%+52.24%+99.37%+175.36%+417.71%SPRYARS Pharmaceuticals-1.10%-7.13%+1.12%-45.00%-40.79%TNGXTango Therapeutics-1.75%+3.33%+18.29%+30.67%+25.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETHZETHZilla$15.64-4.4%$0.00$6.60▼$174.60$257.12M0.38562,881 shs1.86 million shsKODKodiak Sciences$18.05-5.0%$11.86$1.92▼$19.39$953.44M2.67551,130 shs1.23 million shsSPRYARS Pharmaceuticals$9.72-1.8%$11.24$9.34▼$18.90$960.63M0.841.83 million shs1.17 million shsTNGXTango Therapeutics$8.66-3.7%$7.48$1.03▼$9.70$963.51M1.671.84 million shs1.57 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETHZETHZilla-4.44%-14.79%-35.34%+1,635,999,900.00%+1,635,999,900.00%KODKodiak Sciences+7.34%+52.24%+99.37%+175.36%+417.71%SPRYARS Pharmaceuticals-1.10%-7.13%+1.12%-45.00%-40.79%TNGXTango Therapeutics-1.75%+3.33%+18.29%+30.67%+25.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETHZETHZilla 1.00SellN/AN/AKODKodiak Sciences 2.00Hold$13.20-26.87% DownsideSPRYARS Pharmaceuticals 2.86Moderate Buy$33.80247.74% UpsideTNGXTango Therapeutics 2.67Moderate Buy$10.5021.25% UpsideCurrent Analyst Ratings BreakdownLatest ETHZ, TNGX, SPRY, and KOD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ETHZETHZillaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025KODKodiak SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SPRYARS PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TNGXTango TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/6/2025KODKodiak SciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$14.009/27/2025ETHZETHZillaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025KODKodiak SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SPRYARS PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TNGXTango TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/26/2025SPRYARS PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$32.009/25/2025KODKodiak SciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$7.00 ➝ $17.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETHZETHZillaN/AN/AN/AN/A$29.12 per shareN/AKODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/ASPRYARS Pharmaceuticals$89.15M10.78$0.01 per share1,182.06$2.64 per share3.68TNGXTango Therapeutics$42.07M22.90N/AN/A$1.86 per share4.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETHZETHZilla-$6.17M-$15.07N/A∞N/AN/A-141.25%-80.77%11/12/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.80N/AN/AN/AN/A-155.27%-63.29%11/13/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.49N/AN/AN/A-42.74%-21.85%-15.88%11/12/2025 (Estimated)TNGXTango Therapeutics-$130.30M-$1.33N/AN/AN/A-599.11%-79.72%-49.30%11/5/2025 (Estimated)Latest ETHZ, TNGX, SPRY, and KOD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025KODKodiak Sciences-$1.06N/AN/AN/AN/AN/A11/12/2025Q3 2025SPRYARS Pharmaceuticals-$0.45N/AN/AN/A$28.87 millionN/A11/5/2025Q3 2025TNGXTango Therapeutics-$0.07N/AN/AN/A$41.35 millionN/A8/13/2025Q2 2025KODKodiak Sciences-$1.01-$1.03-$0.02-$1.03N/AN/A8/13/2025Q2 2025SPRYARS Pharmaceuticals-$0.41-$0.46-$0.05-$0.46$12.92 million$15.72 million8/5/2025Q2 2025TNGXTango Therapeutics-$0.35-$0.35N/A-$0.35$6.41 million$3.18 million7/23/2025Q2 2025ETHZETHZillaN/A-$3.00N/A-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETHZETHZillaN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETHZETHZillaN/A0.580.58KODKodiak SciencesN/A3.483.48SPRYARS Pharmaceuticals0.376.175.98TNGXTango TherapeuticsN/A4.754.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETHZETHZilla4.07%KODKodiak Sciences89.06%SPRYARS Pharmaceuticals68.16%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipETHZETHZilla5.40%KODKodiak Sciences45.90%SPRYARS Pharmaceuticals33.50%TNGXTango Therapeutics7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETHZETHZilla716.44 million15.56 millionN/AKODKodiak Sciences9052.82 million28.58 millionOptionableSPRYARS Pharmaceuticals9098.83 million65.72 millionOptionableTNGXTango Therapeutics90111.26 million102.92 millionOptionableETHZ, TNGX, SPRY, and KOD HeadlinesRecent News About These CompaniesTango Therapeutics granted orphan designation for treatment of malignant gliomaOctober 16, 2025 | msn.comTango Therapeutics (NASDAQ:TNGX) Reaches New 1-Year High - Here's WhyOctober 14, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Stock Price Up 13.9% - Should You Buy?October 13, 2025 | marketbeat.comBrokerages Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $10.50October 12, 2025 | americanbankingnews.comTango Therapeutics' (TNGX) Sell (E+) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Moderate Buy" by BrokeragesOctober 7, 2025 | marketbeat.comTango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025October 6, 2025 | globenewswire.comInsider Selling: Tango Therapeutics (NASDAQ:TNGX) Major Shareholder Sells 500,000 Shares of StockSeptember 30, 2025 | insidertrades.comTango Therapeutics (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 500,000 SharesSeptember 29, 2025 | marketbeat.comTango Therapeutics, Inc. $TNGX Position Reduced by Goldman Sachs Group Inc.September 29, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Sets New 1-Year High - Time to Buy?September 25, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Shares Up 7% - What's Next?September 24, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Shares Down 5.2% - Here's What HappenedSeptember 22, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Major Shareholder Sells 363,541 SharesSeptember 18, 2025 | insidertrades.comTango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock?September 17, 2025 | zacks.comInsider Selling: Tango Therapeutics (NASDAQ:TNGX) Major Shareholder Sells 86,459 Shares of StockSeptember 10, 2025 | insidertrades.comRock Ventures Iv L.P. Third Sells 302,194 Shares of Tango Therapeutics (NASDAQ:TNGX) StockAugust 27, 2025 | insidertrades.comTango Therapeutics to Participate in the 2025 Cantor Global Healthcare ConferenceAugust 26, 2025 | globenewswire.comTango Therapeutics (NASDAQ:TNGX) Major Shareholder Sells $7,711,000.00 in StockAugust 22, 2025 | insidertrades.comPiper Sandler Initiates Coverage of Tango Therapeutics (TNGX) with Overweight RecommendationAugust 19, 2025 | msn.comTango Therapeutics initiated with an Overweight at Piper SandlerAugust 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETHZ, TNGX, SPRY, and KOD Company DescriptionsETHZilla NASDAQ:ETHZ$15.64 -0.72 (-4.40%) As of 04:00 PM Eastern1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Kodiak Sciences NASDAQ:KOD$18.05 -0.95 (-5.00%) Closing price 04:00 PM EasternExtended Trading$17.60 -0.45 (-2.49%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.ARS Pharmaceuticals NASDAQ:SPRY$9.72 -0.18 (-1.82%) Closing price 04:00 PM EasternExtended Trading$9.85 +0.13 (+1.33%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Tango Therapeutics NASDAQ:TNGX$8.66 -0.33 (-3.67%) Closing price 04:00 PM EasternExtended Trading$8.49 -0.17 (-1.96%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
